Seventure Partners
Seventure Partners is a Paris-based venture capital firm established in 1997, specializing in investments in life sciences and digital technology sectors. With a strong presence in Europe and additional offices in Munich, Geneva, London, and Basel, the firm manages approximately €660 million as of late 2016. Seventure Partners focuses on supporting innovative companies that demonstrate significant growth potential, investing primarily in North America, Europe, Asia-Pacific, the Middle East, and Africa. The firm engages actively with entrepreneurs, providing them with valuable expertise, networks, and resources to accelerate their development. Seventure's investment strategy typically involves funding ranges from €0.5 million to €2 million, aiming to foster the emergence of future European leaders in technology and healthcare. With a team of over 20 professionals, including around 15 investors, Seventure Partners leverages its deep industry knowledge to navigate the venture capital landscape effectively.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
MaaT Pharma, SA, operates as a biotechnology company. It develops therapies to treat diseases related to gut microbiota imbalance. It also develops a series of microbiome-based drugs which targets mortality and comorbidities associated with blood cancer treatment. The company was founded in 2014 and is based in Lyon, France.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.